WPD to Conduct Clinical Trials in Pediatric Brain Tumors

WPD Pharmaceuticals (CSE:WBIO,FSE:8SV1) has announced its plan to initiate a Phase I clinical trial for its treatment for pediatric brain cancer in Poland in collaboration with CNS Pharmaceuticals (NASDAQ:CNSP).

As quoted in the press release:

The Company, in collaboration with CNS, is planning to conduct the upcoming Phase I clinical trial at Children’s Memorial Health Institute (“Children’s Memorial”), the largest pediatric hospital in Poland. The Company believes this Phase I trial of Berubicin at Children’s Memorial represents the first ever investigation of an anthracycline and topoisomerase II inhibitor in pediatric brain tumors. WPD and CNS are currently working with experts at Children’s Memorial to complete documentation for the upcoming study and scientific advice meeting.

Click here to read the full press release.